C
C. Mascaux
Researcher at Aix-Marseille University
Publications - 27
Citations - 1481
C. Mascaux is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 11, co-authored 27 publications receiving 826 citations. Previous affiliations of C. Mascaux include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Julien Mazieres,Alexander Drilon,Amélie Lusque,Laurent Mhanna,Alexis B. Cortot,Laura Mezquita,A. Thai,C. Mascaux,Sébastien Couraud,Remi Veillon,M. van den Heuvel,Joel W. Neal,Nir Peled,Martin Früh,Terry L. Ng,Valérie Gounant,Sanjay Popat,Joachim Diebold,Joshua K. Sabari,Viola W. Zhu,Sacha I. Rothschild,Paolo Bironzo,Alex Martinez-Marti,Alessandra Curioni-Fontecedro,Rafael Rosell,Mickaël Lattuca-Truc,Marcel Wiesweg,Benjamin Besse,Benjamin Solomon,Fabrice Barlesi,R.D. Schouten,Heather A. Wakelee,D.R. Camidge,Gérard Zalcman,Silvia Novello,S-H.I. Ou,Julie Milia,Oliver Gautschi +37 more
TL;DR: In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2) and the lack of response in the ALK group was notable.
Journal ArticleDOI
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Catherine Labbé,Michael Cabanero,Grzegorz Korpanty,Pascale Tomasini,Mark Doherty,C. Mascaux,Kevin Jao,Bethany Pitcher,Rick Wang,Melania Pintilie,Natasha B. Leighl,Ronald Feld,Geoffrey Liu,Penelope A. Bradbury,Suzanne Kamel-Reid,Ming-Sound Tsao,Frances A. Shepherd +16 more
TL;DR: Patients with dual TP53/EGFR mutations, especially missense mutations, had marginally lower response rates and shorter PFS when treated with EGFR TKI therapy, and larger datasets are required to validate these observations.
Journal ArticleDOI
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Arnaud Jeanson,Pascale Tomasini,Pascale Tomasini,M. Souquet-Bressand,Nicolas Brandone,Mohamed Boucekine,M. Grangeon,S. Chaleat,Natalyia Khobta,Julie Milia,Laurent Mhanna,Laurent Greillier,Laurent Greillier,Julie Biemar,Isabelle Nanni,L'Houcine Ouafik,Stéphane Garcia,Julien Mazieres,Fabrice Barlesi,Fabrice Barlesi,C. Mascaux,C. Mascaux +21 more
TL;DR: For patients with KRAS-mutant NSCLC (all mutational subtypes), the efficacy of ICI is similar to that for patients with other types of NSCLCs, and this finding is especially true when PD-L1 expression is high (PD-L 1 expression ≥50%).
Journal ArticleDOI
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer
M. Grangeon,Pascale Tomasini,S. Chaleat,Arnaud Jeanson,M. Souquet-Bressand,N. Khobta,J. Bermudez,Y. Trigui,Laurent Greillier,Marilyne Blanchon,Mohamed Boucekine,C. Mascaux,Fabrice Barlesi +12 more
TL;DR: This report presents the largest case series showing longer OS and PFS and better ORR when IRAEs occurred in a population of patients with advanced NSCLC treated with ICIs.
Journal Article
[VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis]
Philippe Delmotte,Benoît Martin,Marianne Paesmans,Thierry Berghmans,C. Mascaux,Anne-Pascale Meert,Emmanuelle Steels,Jean-Marc Verdebout,Jean-Jacques Lafitte,Jean-Paul Sculier +9 more
TL;DR: A systematic review of the English and French literature on VEGF and its effect on the survival of patients with small cell and non-small cell lung cancer concluded that the expression of V EGF in MSCLC is a factor indicating a poor prognosis.